01482nas a2200481   4500000000100000000000100001008004100002653003100043653004400074653005600118653004200174653001100216653004300227653003000270653002400300653006700324653002600391653002200417653000900439653004000448653003200488653000900520653000900529100001400538700001500552700001300567700001300580700001500593700001200608700001500620700001400635700001200649700001500661700001500676700001400691700001500705700001800720245019500738250001500933300001400948490000700962020003100969       2022                            d10aAdministration, Inhalation10aAdrenal Cortex Hormones/adverse effects10aAdrenergic beta-2 Receptor Agonists/adverse effects10aBronchodilator Agents/adverse effects10aHumans10aMuscarinic Antagonists/adverse effects10aNebulizers and Vaporizers10aPrimary health care10a*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy10aRetrospective Studies10aTreatment Outcome10aCopd10aclinical practice research datalink10aHospital Episode Statistics10aMitt10aSitt1 aD. Halpin1 aK. Rothnie1 aV. Banks1 aA. Czira1 aC. Compton1 aR. Wood1 aT. Tritton1 aO. Massey1 aR. Wild1 aN. Snowise1 aK. Nikitin1 aR. Sharma1 aA. Ismaila1 aC. Vogelmeier00aComparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting  a2022/10/04  a2417-24290 v17  a1176-9106 (Print)1176-9106